Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.685 USD | +1.94% | -34.89% | -16.00% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.00% | 245M | |
+12.16% | 225B | |
+10.80% | 186B | |
+13.24% | 135B | |
+25.55% | 107B | |
+0.87% | 63.56B | |
+5.62% | 51.32B | |
+12.52% | 51.04B | |
+8.33% | 43.3B | |
+5.01% | 36.99B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Morgan Stanley Lowers Price Target for NeuroPace to $9 From $12, Maintains Underweight Rating